Alnylam Pharmaceuticals, Inc.

Jeffrey Zuber

Mark K Schlegel

James D McIninch

Adam Castoreno

Lucas D BonDurant

Jonathan Edward Farley

Stephen Abbott

Joseph Barry

Tyler Chickering

Dhaval Oza

Lauren Blair Woods

Lucas Bondurant

The disclosure relates to double stranded ribonucleic acid interference (dsRNAi) agents and compositions targeting a microtubule-associated protein tau (MAPT) gene, as well as methods of inhibiting expression of a MAPT gene and methods of treating subjects having a MAPT-associated disease or disorder, e.g., Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, or other tauopathies, using such dsRNAi agents and compositions.

Microtubule associated protein Tau (MAPT) iRNA agent compositions and methods of use thereof

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the CIDEB gene, as well as methods of inhibiting expression of CIDEB, and methods of treating subjects that would benefit from reduction in expression of CIDEB, such as subjects having a CIDEB-associated disease, disorder, or condition, using such dsRNA compositions.

Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof

The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the Angiopoietin-like 3 (ANGPTL3) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an ANGPTL3 gene and to methods of preventing and treating an ANGPTL3-associated disorder, e.g., a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia.

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

Growing community of inventors

Somerville, MA, United States of America

Jeffrey Zuber